Vcanbio Cell & Gene Engineering Corp Interest Expense
The Interest Expense of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Oct 12, 2026 is -28.17 M CNY. In the previous year, Interest Expense was -21.86 M CNY — a change of 28.86% (lower).
Get this data via API
Financial Data API
Interest Expense
-28.17 MCNY
YoY
28.86%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Interest Expense history
3 Years
10 Years
25 Years
Max
| YEAR | Interest Expense | YoY |
|---|---|---|
| -28.17 MCNY | +28.86% | |
| -21.86 MCNY | -1,759.26% | |
| 1.32 MCNY | -98.57% | |
| 92.07 MCNY | -5,214.91% | |
| -1.80 MCNY | -94.32% | |
| -31.70 MCNY | -135.50% | |
| 89.30 MCNY | -240.41% | |
| -63.60 MCNY | +127.96% | |
| -27.90 MCNY | -118.65% | |
| 149.60 MCNY | +3,224.44% | |
| 4.50 MCNY | — |
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Interest Expense of Vcanbio Cell & Gene Engineering Corp is -28.17 M CNY in 2024.
Interest Expense of Vcanbio Cell & Gene Engineering Corp changed from -21.86 M CNY to -28.17 M CNY, representing a 28.86% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Interest Expense Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.
Interest Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's Vcanbio Cell & Gene Engineering Corp historically and in real time.
Income Statement — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth